162 related articles for article (PubMed ID: 32068002)
1. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial.
Butler J; Khan MS; Anker SD; Fonarow GC; Kim RJ; Nodari S; O'Connor CM; Pieske B; Pieske-Kraigher E; Sabbah HN; Senni M; Voors AA; Udelson JE; Carr J; Gheorghiade M; Filippatos G
J Card Fail; 2020 May; 26(5):429-437. PubMed ID: 32068002
[TBL] [Abstract][Full Text] [Related]
2. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide.
Daubert MA; Yow E; Dunn G; Marchev S; Barnhart H; Douglas PS; O'Connor C; Goldstein S; Udelson JE; Sabbah HN
Circ Heart Fail; 2017 Dec; 10(12):. PubMed ID: 29217757
[TBL] [Abstract][Full Text] [Related]
3. Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure.
Sabbah HN; Gupta RC; Kohli S; Wang M; Hachem S; Zhang K
Circ Heart Fail; 2016 Feb; 9(2):e002206. PubMed ID: 26839394
[TBL] [Abstract][Full Text] [Related]
4. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial.
Chung ES; Miller L; Patel AN; Anderson RD; Mendelsohn FO; Traverse J; Silver KH; Shin J; Ewald G; Farr MJ; Anwaruddin S; Plat F; Fisher SJ; AuWerter AT; Pastore JM; Aras R; Penn MS
Eur Heart J; 2015 Sep; 36(33):2228-38. PubMed ID: 26056125
[TBL] [Abstract][Full Text] [Related]
5. Danish phase II trial using adipose tissue derived mesenchymal stromal cells for patients with ischaemic heart failure.
Qayyum AA; Mouridsen M; Nilsson B; Gustafsson I; Schou M; Nielsen OW; Hove JD; Mathiasen AB; Jørgensen E; Helqvist S; Joshi FR; Johansen EM; Follin B; Juhl M; Højgaard LD; Haack-Sørensen M; Ekblond A; Kastrup J
ESC Heart Fail; 2023 Apr; 10(2):1170-1183. PubMed ID: 36638837
[TBL] [Abstract][Full Text] [Related]
6. Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction.
Abdul-Rahim AH; Shen L; Rush CJ; Jhund PS; Lees KR; McMurray JJV;
Eur J Heart Fail; 2018 Jul; 20(7):1139-1145. PubMed ID: 29493058
[TBL] [Abstract][Full Text] [Related]
7. Targeting mitochondrial dysfunction with elamipretide.
Obi C; Smith AT; Hughes GJ; Adeboye AA
Heart Fail Rev; 2022 Sep; 27(5):1925-1932. PubMed ID: 35037146
[TBL] [Abstract][Full Text] [Related]
8. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study.
Lupón J; Díez-López C; de Antonio M; Domingo M; Zamora E; Moliner P; González B; Santesmases J; Troya MI; Bayés-Genís A
Eur J Heart Fail; 2017 Dec; 19(12):1615-1623. PubMed ID: 28387002
[TBL] [Abstract][Full Text] [Related]
9. Autonomic regulation therapy via left or right cervical vagus nerve stimulation in patients with chronic heart failure: results of the ANTHEM-HF trial.
Premchand RK; Sharma K; Mittal S; Monteiro R; Dixit S; Libbus I; DiCarlo LA; Ardell JL; Rector TS; Amurthur B; KenKnight BH; Anand IS
J Card Fail; 2014 Nov; 20(11):808-16. PubMed ID: 25187002
[TBL] [Abstract][Full Text] [Related]
10. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.
Jorsal A; Kistorp C; Holmager P; Tougaard RS; Nielsen R; Hänselmann A; Nilsson B; Møller JE; Hjort J; Rasmussen J; Boesgaard TW; Schou M; Videbaek L; Gustafsson I; Flyvbjerg A; Wiggers H; Tarnow L
Eur J Heart Fail; 2017 Jan; 19(1):69-77. PubMed ID: 27790809
[TBL] [Abstract][Full Text] [Related]
11. Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial.
Jensen J; Omar M; Kistorp C; Poulsen MK; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Faber J; Fosbøl EL; Bruun NE; Brønd JC; Forman JL; Videbæk L; Møller JE; Schou M
Am Heart J; 2020 Oct; 228():47-56. PubMed ID: 32798787
[TBL] [Abstract][Full Text] [Related]
12. Phenotyping Heart Failure According to the Longitudinal Ejection Fraction Change: Myocardial Strain, Predictors, and Outcomes.
Park JJ; Mebazaa A; Hwang IC; Park JB; Park JH; Cho GY
J Am Heart Assoc; 2020 Jun; 9(12):e015009. PubMed ID: 32519555
[TBL] [Abstract][Full Text] [Related]
13. Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial.
Voors AA; Tamby JF; Cleland JG; Koren M; Forgosh LB; Gupta D; Lund LH; Camacho A; Karra R; Swart HP; Pellicori P; Wagner F; Hershberger RE; Prasad N; Anderson R; Anto A; Bell K; Edelberg JM; Fang L; Henze M; Kelly C; Kurio G; Li W; Wells K; Yang C; Teichman SL; Del Rio CL; Solomon SD
Eur J Heart Fail; 2020 Sep; 22(9):1649-1658. PubMed ID: 32558989
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial.
Voors AA; Bax JJ; Hernandez AF; Wirtz AB; Pap AF; Ferreira AC; Senni M; van der Laan M; Butler J;
Eur J Heart Fail; 2019 Nov; 21(11):1426-1433. PubMed ID: 31523892
[TBL] [Abstract][Full Text] [Related]
15. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
Armstrong PW; Roessig L; Patel MJ; Anstrom KJ; Butler J; Voors AA; Lam CSP; Ponikowski P; Temple T; Pieske B; Ezekowitz J; Hernandez AF; Koglin J; O'Connor CM
JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136
[TBL] [Abstract][Full Text] [Related]
16. Design of a Phase 3 trial of intracoronary administration of human adenovirus 5 encoding human adenylyl cyclase type 6 (RT-100) gene transfer in patients with heart failure with reduced left ventricular ejection fraction: The FLOURISH Clinical Trial.
Penny WF; Henry TD; Watkins MW; Patel AN; Hammond HK
Am Heart J; 2018 Jul; 201():111-116. PubMed ID: 29763816
[TBL] [Abstract][Full Text] [Related]
17. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
Jensen J; Omar M; Kistorp C; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Faber J; Malik ME; Fosbøl EL; Bruun NE; Forman JL; Jensen LT; Møller JE; Schou M
Lancet Diabetes Endocrinol; 2021 Feb; 9(2):106-116. PubMed ID: 33357505
[TBL] [Abstract][Full Text] [Related]
18. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
Santos-Gallego CG; Vargas-Delgado AP; Requena-Ibanez JA; Garcia-Ropero A; Mancini D; Pinney S; Macaluso F; Sartori S; Roque M; Sabatel-Perez F; Rodriguez-Cordero A; Zafar MU; Fergus I; Atallah-Lajam F; Contreras JP; Varley C; Moreno PR; Abascal VM; Lala A; Tamler R; Sanz J; Fuster V; Badimon JJ;
J Am Coll Cardiol; 2021 Jan; 77(3):243-255. PubMed ID: 33197559
[TBL] [Abstract][Full Text] [Related]
19. Heart Failure and Midrange Ejection Fraction: Implications of Recovered Ejection Fraction for Exercise Tolerance and Outcomes.
Nadruz W; West E; Santos M; Skali H; Groarke JD; Forman DE; Shah AM
Circ Heart Fail; 2016 Apr; 9(4):e002826. PubMed ID: 27009553
[TBL] [Abstract][Full Text] [Related]
20. PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial.
Kim KH; Kim HK; Hwang IC; Cho HJ; Je N; Kwon OM; Choi SJ; Lee SP; Kim YJ; Sohn DW
Am Heart J; 2015 Jun; 169(6):813-822.e3. PubMed ID: 26027619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]